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Abstract
Background: Apolipoprotein B (APOB) is an integral component of the chylomicron and the atherogenic
lipoproteins LDL and Lp(a). Exon 26 of the APOB pre-mRNA is unusually long at 7,572 nt and is constitutively
spliced. It is also subject to RNA editing in the intestine, which generates a shortened isoform, APOB48, assembled
exclusively into chylomicrons. Due to its length, exon 26 contains multiple pseudo splice sites which are not
spliced, but which conform to the degenerate splice site consensus.
Results: We demonstrate that these pseudo splice sites are repressed by multiple, tandem splicing silencers
distributed along the length of exon 26. The distribution of these elements appears to be heterogeneous, with a
greater frequency in the middle 4,800 nt of the exon.
Conclusion: Repression of these splice sites is key to maintaining the integrity of exon 26 during RNA splicing and
therefore the correct expression of both isoforms of APOB.
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Background
Apolipoprotein B (APOB) is a component of the LDL,
Lp(a) and chylomicron lipoprotein particles [1]. The full-
length APOB100 isoform is mainly synthesized in the
liver and is assembled into LDL and Lp(a). The pre-
mRNA is subject to intestine-specific RNA editing by a
complex known as the editosome, which includes a cata-
lytic subunit, APOBEC-1, and several auxiliary factors.
Editing occurs in exon 26 at position 6666 of the mRNA
converting a C to a U, generating a premature termin-
ation codon (PTC), and producing a C-terminal trun-
cated isoform, APOB48. This isoform is assembled into
the chylomicron particle and is unable to bind the LDL
receptor [2]. The constitutively spliced exon 26 of APOB
is also unusual in that it is 7,572 nt long, far longer than
the mean length of exons in the genome at 145 nt [3].
Pre-mRNA contains sequence elements defining the
50 and 30 ends of introns and the branch point. In mam-
mals, the consensus sequences of these elements are
highly degenerate [4]. As a result, matches to these con-
sensus sequences are highly prevalent throughout the
genome [5] and outnumber genuine splice sites by an
order of magnitude in the human HPRT gene [6]. These
pseudo splice sites are not normally employed in spli-
cing. How the spliceosome is able to differentiate the
few genuine splice sites from numerous pseudo splice
sites is as yet unclear.
Other sequences within the pre-mRNA have been sug-
gested to influence the choice between pseudo splice
sites and genuine splice sites to allow accurate and re-
producible splicing at the latter. Exonic and intronic
splicing enhancer sequences (ESE and ISE, respectively)
have been characterized, and in general these act by
binding SR proteins which interact with the spliceosome
to favour the use of particular splice sites [7-9]. Intronic
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and exonic splicing silencer sequences (ISS and ESS, re-
spectively), which discourage the use of particular splice
sites, have also been identified on functional and bio-
informatic grounds [5,8,10]. Silencing elements bind si-
lencing factors such as hnRNP A1 [11], polypyrimidine
tract binding protein [12] and hnRNP H [13]. The bal-
ance between enhancing factors (e.g. SF2) and silencing
factors (e.g. hnRNP A1) determines the selection of
splice sites and alternative splicing [14,15].
Most of the pseudo splice sites in the human genome
reside in introns, by virtue of their long lengths [5,6].
Long exons such as APOB exon 26, also contain many
pseudo splice sites (vide infra). Correctly orientated
pseudo 30 and 50 splice sites should trigger exon defin-
ition and erroneous splicing within the exon 26 se-
quence [16]. Alternatively, the genuine splice sites could
be identified via a process of intron definition. This re-
lies on the recognition of 50 and 30 splice site pairs over
short introns <100 nt in Drosophila [17]. In human nu-
clear extracts and in HeLa cells, intron definition
appears to operate below a threshold of 200–250 nt [18].
Intron definition, therefore, cannot easily explain the
splicing of APOB exon 26 as the upstream intron Y and
the downstream intron Z are too long at 506 and 403 nt
respectively. APOB exon 26 provides a crucial test case
for the hypothesis that the configuration of ESE and ESS
within the pre-mRNA is important for the accurate and
reproducible splicing of long exons.
Results and discussion
APOB exon 26 contains many pseudo splice sites
In order to assess the number of pseudo splice sites
within APOB exon 26, we scanned the genomic se-
quence of APOB for matches to the 50 and 30 splice sites
consensus sequences using the position score matrix of
Shapiro and Senapathy [4]. A higher score out of 100
indicates a stronger splice site, and provides an estimate
of the likelihood of a sequence being identified as an
exon boundary and utilised in splicing. The genuine
splice sites delineating the internal exons 2–28 were
identified (Additional file 1: Table S1). The weakest
50 splice site was that of exon 27 (score: 63.5) and the
weakest 30 splice site was that of exon 20 (score: 74.7).
Using 63.5 and 74.7 respectively as the thresholds for
the search, 54 50 splice sites with scores ≥63.5 and 103
30 splice sites with scores ≥74.7 were identified within
the sequence of APOB exon 26 (Figure 1).
The 30 splice site flanking exon 26 scored 83.2 and the
50 splice site scored 86.5 (combined score 169.7). Using
the exon 26 flanking scores of 83.2 and 86.5 as thresh-
olds, 32 30 splice sites and two 50 splice sites within exon
26 were identified as closer matches to the consensus
with higher scores than the genuine splice sites flanking
exon 26. On theoretical grounds, therefore, each of these
pseudo splice sites could be used in preference to the
genuine splice sites, generating two possible 30 shortened
alternatives combining the 50 pseudo splice sites with the
30 splice site flanking exon 27, and 32 possible 50 shor-
tened alternatives combining the 30 pseudo splice sites
with the 50 splice site flanking exon 25.
A search was also made for plausible pseudo-exons
within the length of exon 26 using this subset of high-
scoring pseudo splice sites. These were defined as
sequences bounded by 30 and 50 pseudo splice sites in
the right orientation, with lengths of 39–374 bp, these
being the range of lengths for the other APOB internal
exons. Using these criteria at least 3 alternative pseudo-
exons could be identified that contain pseudo splice sites
that are a better fit to the consensus than the genuine
splice sites, and which on these bioinformatic criteria
are more plausible exons than exon 26 itself.
Using an alternative method to identify splice sites,
Maximum Entropy Modelling (see Additional file 2:
Table S2) of the same region identified five 30 splice sites
and one alternative 50 splice site within exon 26 which
score higher than the native 30 and 50 splice sites [19].
Again using the same criteria, one strong pseudo-exon
of 143 bp, with an appropriately positioned high scoring
branch site was identified (position 4906–5048) [20].
Both these methods therefore identify plausible pseudo-
exons which should in theory be spliced into the APOB
mRNA instead of the actual exon 26.
APOB exon 26 contains multiple silencing sequences
along its length
We hypothesized that ESS might be responsible for silen-
cing the pseudo splice sites, with two possible architectures
for ESS in exon 26. Firstly, a single or a few strong ESS
sequences might exist which are able to influence large
areas of exon 26, similar to hnRNP A1. This is able to bind
to high affinity sites, cooperatively bind, propagate along
an exon, and antagonize SR protein function [21]. In this
context it should be noted that exon 26 contains sequences
that resemble consensus high-affinity hnRNP A1 sites [22]
such as 2666–2671 (UAGAGU – found in construct 7 of
Figure 2B) and 4114–4119 (UAGGGA – found in con-
struct 11 of Figure 2B). Secondly, exon 26 might contain
multiple ESS distributed along the length of the exon.
The length of exon 26 makes it difficult to test for the
existence of ESE and ESS in exon 26 in their native con-
text. Therefore, we turned to a heterologous splicing re-
porter, DNA ligase III. This two-exon construct contains a
C exon and an alternatively spliced ß exon which is con-
trolled by an ESS within the ß exon. Deletion of the ESS
allows C to splice to ß efficiently in vitro [23]. Candidate
sequences derived from exon 26 were therefore cloned at
the 30 end of the ß exon, replacing the native ESS, and
these constructs were transcribed and tested for splicing
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in vitro (Figure 2A). Suppression of C-ß splicing indicates
presence of ESS activity within the candidate sequence.
Figure 2B shows the results of testing non-overlapping
400 nt fragments derived from exon 26 in this system.
DNA ligase III C-ß splices efficiently, as does a control
construct containing 339 nt of IGF-I exons 3 and 4,
tagged to the 30 end of DNA ligase III C-ß (see lanes Cß
and I3+4). However, tagging 376–400 nt fragments of
exon 26 causes silencing of splicing of the C-ß intron
(lanes 1–19), with variable silencing activity – compare
lanes 1–4, 17, 18 with lanes 5–16, 19. Silencing activity
appears to be strongest in the middle 4800 nt of sequence
corresponding to fragments 5–16.
We conclude, therefore, that the sequence of exon 26
contains splicing silencing activity throughout its length,
but that this activity is heterogeneously distributed.
There is no evidence of a single super-ESS in exon 26,
for example centered around the potential high-affinity
hnRNP A1 sites.
Microarchitecture of ESS in exon 26
In order to further investigate the distribution of ESS in
exon 26, overlapping 25 nt sequences derived from frag-
ment 1 and from fragment 6 were tested using the DNA
ligase III in vitro splicing system. We selected fragment
1 and fragment 6 as exemplars of relatively well-spliced
and relatively silenced fragments respectively. More-
over, as fragment 6 contains the RNA editing site, we
wished to see if silencing activity was related to the
RNA editing activity.
Figure 3A shows the result of testing these constructs,
made with sequences derived from fragment 1. At this
resolution, there is a heterogeneous distribution of ESS
activity, with certain sequences such as 65–89 showing
silencing better than the native ESS of DNA ligase III,
REP and other sequences such as 113–137 showing no
significant effects on splicing (Figure 3B). Identically
spliced mRNAs appear as different sized bands in the
lower parts of Figures 3A and 4A. This is likely to repre-
sent variable degrees of exonuclease degradation to
which mRNAs are susceptible in the nuclear extract
used for the assay.
Figure 4 shows the result of testing constructs made
with sequences derived from fragment 6. In contrast to
the fragment 1 sequences, the fragment 6 sequences show
less heterogeneity with most sequences tested showing
ESS activity (see Figure 4A and 4B). We conclude, there-
fore, that exon 26 contains multiple ESS sequences along
Figure 1 Shapiro and Senapathy [4] scores for pseudo splice sites scoring higher than the lowest-scoring genuine APOB splice sites.
The dotted lines show the scores of the genuine splice sites flanking exon 26. (A) Scores of 50 splice sites (ordinate) plotted against position in
exon 26 (abscissa). (B) Scores of 30 splice sites (ordinate) plotted against position of the in exon 26 (abscissa). The arrow indicates the pseudo
splice site that is used in the alternative splicing event identified in Figure 6. (C) Table of positions and Shapiro and Senapathy scores of pseudo
50 splice sites in exon 26 scoring higher than the native 50 splice site at position 7572. (D) Table of positions and Shapiro and Senapathy scores of
pseudo 30 splice sites in exon 26 scoring higher than the native 30 splice site at position 1. The asterisk indicates the pseudo splice site that is
used in the alternative splicing event identified in Figure 6.
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its length in a heterogeneous distribution. More frequent
silencing activity is seen with the 25-mers derived
from fragment 6 than fragment 1, consistent with the
greater silencing activity of fragment 6 compared to
fragment 1.
ESS identified by the DNA ligase III C-ß reporter also
silence the HßΔ6 reporter
In order to ensure that the ESS activity was not dependent
on the splicing reporter, key sequences were also tested in
the ß-globin splicing reporter HßΔ6 [23,24]. In this differ-
ent context, the 25-mers 65–89 and 2319–2343 ED were
also able to repress HßΔ6 splicing by ~50%, whereas the
neutral sequence 161–185 did not significantly repress
splicing (Figure 5).
The sequence requirements of RNA editing are distinct
from ESS activity
RNA editing of APOB is dependent on an 11 nt mooring
sequence 30 to the RNA editing site itself, which repre-
sents a binding site for the editosome [25]. The sequence
spanning the RNA editing site and mooring sequence
(ED) shows ESS activity (see Figure 4A, lane 2319–2343
ED). As RNA editing and splicing are linked [26] and as
both processes may share common components, such as
KSRP [27] and CUGBP2 [28], we wondered whether the
silencing activity of ED might be related to its ability to
support RNA editing. To this end, several point muta-
tions were constructed in ED, three of which are known
to knock out RNA editing (T9A, T9C, A11C), one of
which is neutral with respect to RNA editing (G15C),
and one of which is intermediate in reducing RNA
Figure 2 Structure of the DNA ligase III splicing reporter and in vitro splicing assay of exon 26 sequences. (A) Top Schematic showing
the genomic structure of APOB exon 26 and adjacent exons. Boxes represent exons, the lines interconnecting exons represent introns. Numbers
above exons and introns represent lengths of the respective elements in nucleotides. Exon 26 is divided into 400 nt fragments labelled 1 to 18.
Note that fragment 19 is shorter than fragments 1–18 at 372 nt. Bottom shows fragment 5 in position at the 30 end of the DNA ligase III splicing
reporter, replacing the native ESS. (B) In vitro splicing of A constructs: 10% PAGE shown. Lanes M = pBR322-MspI digest marker; Cß = DNA ligase
III C-ß construct without ESS; I3+4 = DNA ligase III C-ß with IGF-I exons 3 and 4 tagged to 30 end; 1–19 = fragment 1 to 19 constructs. Adjacent
cartoons show identity of bands. Note that the migration of the splicing intermediates of the DNA ligase III C-ß reporter is characteristically
retarded on this high percentage gel. (C) Graph showing relative splicing efficiency of constructs, normalised to 100% = splicing efficiency of
DNA ligase III C-ß construct without ESS.
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editing activity (A19T) [28]. These constructs were
tested for splicing activity (see Figure 4A, right-hand 5
lanes). The mutations did not affect the silencing activity
of ED, suggesting that the sequence requirements of
RNA editing are distinct from ESS activity and that per-
haps different factors are responsible for silencing activ-
ity vis-à-vis RNA editing.
Antisense oligonucleotide blockade of ESS causes
alternative splicing of APOB
To investigate the role of these ESS elements in vivo,
we turned to 20-O-methyl antisense oligonucleotides
(ASOs), which can direct alternative splicing by binding
to splice sites or regulatory elements [29,30]. These
ASOs were targeted at identified ESS, namely elements
Figure 3 Microarchitecture of ESS activity in exon 26 sequences derived from fragment 1. (A) In vitro splicing assay of DNA ligase III C-ß
splicing reporter, tagged with 25-mers derived from fragment 1 (1 hour splicing at 30°C). 10% PAGE shown. Lanes Cß = DNA ligase III C-ß
construct without ESS; Cß ex27 1–25 = Cß + nt 1–25 of exon 27; Cß REP = Cß + native ESS; Cß IGF-I ex3 1–25 = Cß + nt 1–25 of exon 3 from
IGF-I; DL3 Cß ex 26 lanes = nts of exon 26 shown. Adjacent cartoons show identity of bands. (B) Quantification of splicing efficiency, normalised
to DNA ligase III C-ß reporter. Bars show splicing efficiency from n=4 experiments with DNA ligase III C-ß = 100%. Error bars show S.E.M. Overall
one-way ANOVA shows p <0.0001. Comparison to DNA ligase III C-ß for each construct by Bonferroni’s multiple comparison test: statistically
significant differences from efficiency of DNA ligase III C-ß splicing shown by *= p <0.01, **= p <0.001.
Figure 4 Microarchitecture of ESS activity in exon 26 sequences derived from fragment 6. (A) In vitro splicing assay of DNA ligase III C-ß
splicing reporter, tagged with 25-mers derived from fragment 6 (1 hour splicing at 30°C). 10% PAGE shown. Lanes Cß = DNA ligase III C-ß
construct without ESS; Cß ex27 1–25 = Cß + nt 1–25 of exon 27; Cß REP = Cß + native ESS; Cß IGF-I ex3 1–25 = Cß + nt 1–25 of exon 3 from
IGF-I; DL3 Cß ex 26 lanes = nts of exon 26 tested are shown above each lane; lane 2319–2343 encompasses the RNA editing site and mooring
sequence (ED); ED sequence mutations T9A, T9C, A11C, G15C, A19T shown in right-hand five lanes. Adjacent cartoons show identity of bands. (B)
Quantification of splicing efficiency, normalised to DNA ligase III C-ß reporter. Bars show splicing efficiency from n=4 experiments with DNA ligase
III C-ß = 100%. Error bars show S.E.M. Overall one-way ANOVA shows p <0.0001. Comparison to DNA ligase III C-ß for each construct by Bonferroni’s
multiple comparison test: statistically significant differences from efficiency of DNA ligase III C-ß splicing shown by *= p <0.01, **= p <0.001.
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66–89, 97–121, 129–153, 2319–2343 ED (Figure 6:
labelled - respectively). We also made an ASO targeted
to a neutral region, 193–217 (labelled), and a negative
control ASO which did not match any sequences
within APOB. These ASOs were transfected into
HepG2 cells, which synthesize and secrete APOB. The
splicing of APOB exon 26 was assessed by RT-PCR
[30].
As shown in Figure 6, targeting ASOs individually to
each ESS did not cause significant alternative splicing
(compare lanes 2 and 3 with lanes 4–7). Targeting the
neutral sequence 193–217 did not alter splicing (com-
pare lanes 2 and 3 with lane 8). Targeting another
neutral sequence 2191–2215 did not alter splicing
(Additional file 3: Figure S1: compare lane 6 with lane
2). However, when mixtures of ASOs were combined,
especially when ESS 66–89, 97–121 and 129–153 were
targeted simultaneously, we saw significant alternative
splicing of APOB to two alternative isoforms (compare
lanes 2 and 3 with lanes 9–13): one in which exon 26
was skipped to join exons 25 and 27 together; and one
in which a pseudo 30 splice site (Shapiro and Senapa-
thy score 90.4 and Maximum Entropy Modelling score
10.04) was selected at position 7048 within exon 26
(see also Figure 1B – this splice site is indicated with
the arrow). Maximum Entropy Modelling ranks this
pseudo 30 site as the highest scoring and strongest 30 site
within APOB exon 26 (Additional file 2: Table S2), in com-
parison to the native 30 splice site (score 7.68). This there-
fore implies that: (1) these elements have a function in
suppressing pseudo splice site selection in vivo; and (2) that
these elements have functional redundancy.
While the splice site strength of this cryptically acti-
vated 30 splice site is higher than the native 30 splice
site it is unclear why a group of ESS approximately
7,000 nt upstream might be involved in repressing this
pseudo splice site. We may speculate that disruption
of exonic silencers allows more efficient aggregation
of splicing factors around cryptic splice sites further
downstream, thereby increasing the kinetics of spli-
ceosome assembly and allowing minor isoforms to
become apparent. The other possibility is that interfer-
ence with ESS allows silencing protein activity to be-
come more influential at the constitutive 30 splice site.
Other methodological explanations include the possi-
bility that pseudo splice sites nearer the ESS sites are
selected which would give significantly larger products
which were not amplified efficiently by the PCR in
comparison to the shorter transcripts, or that could
not be distinguished from constitutively spliced tran-
script by gel electrophoresis under the conditions
which we used.
Figure 5 Activity of key ESS sequences in the context of HßΔ6. (A) The indicated sequences from exon 26 were cloned into the AccI site of
exon 2 and tested for in vitro splicing activity (2 hour incubation, 30°C). 5% PAGE shown. Adjacent cartoons show identity of bands. (B)
Quantification of splicing efficiency, normalised to HßΔ6 reporter. The bars show splicing efficiency, normalised to HßΔ6 for n=9 experiments,
error bars show S.E.M. Overall one-way ANOVA shows p <0.0001. Comparison to HßΔ6 splicing efficiency for each construct by Bonferroni’s
multiple comparison test: statistically significant differences shown by **= p <0.001.
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Computational identification of ESS is less specific and
sensitive than splicing assays
Experimental and computational models, such as FAS-
ESS hexamers and putative ESS (PESS) octamers as
defined by Zhang and Chasin [8], can be used to predict
ESS sites in exon 26 and which may then be compared
with sites identified in our assay. FAS-ESS hexamers
appear to occur along the exon 26 sequence (Additional
file 4: Figure S2), but there does not appear to be any bias
towards more frequent appearances within the middle of
the exon as noted in our assay. We found that there was a
variable correlation of FAS-ESS hexamers within 25mer
ESS identified in our assays (Additional file 5: Figure S3
and Additional file 6: Figure S4) but overall these appear
to be less sensitive (50%) and less specific (40%) than the
in vitro splicing assay. A similar picture was again appar-
ent with the PESS matches (Additional file 5: Figure S3
and Additional file 6: Figure S4).
It has also been suggested that the distribution of spli-
cing enhancer sequences can influence the use of genu-
ine splice sites over pseudo splice sites. We therefore
searched for ESE sequences within exon 26, using tools
derived from computational and experimental modeling
[7,8,31-33] to see if there might be such a bias in the dis-
tribution of ESE. However, putative ESE were noted all
along the length of the exon and do not appear to have
a bias for the ends of the exons, in keeping with other
similar studies [34], suggesting that ESE do not appear
to contribute to the selection of genuine splice sites in
exon 26. This is further confirmed by the fact that we
did not detect any significant enhancement of reporter
splicing by the tested sequences.
Secondary structure
A prediction of the secondary structure folding of APOB
exon 26 pre-mRNA and its flanking introns, utilising the
mfold web server (see Additional file 7: Table S3) shows
that Region A6, which has inherently higher silencing ac-
tivity compared with region A1, is predicted to contain
more secondary structure [35]. In particular, the ESS con-
taining the editing site, targeted by ASO (2319–2343),
contains a high degree of secondary structure (76% of the
sequence predicted to be base-paired). Work by Hiller and
colleagues [36] suggests that splicing elements are more
Figure 6 Antisense oligonucleotides directed against identified ESS elements cause alternative splicing of APOB in HepG2 cells. In lanes
1 and 2 the cells were not transfected with ASOs. The –RT control PCR (lane 1) was performed without reverse transcriptase. In lane 3, the cells
were transfected with negative control ASO at 500 nM. Lanes 4–13 were transfected with the indicated ASOs at 125 nM each; the total
concentration of ASO was adjusted to 500 nM with negative control ASO. Cells were incubated for 48 hours and RT-PCR was carried out on the
total RNA extracted from these cells with oligonucleotides annealing to the adjacent exons 25 and 27. The positions of the bands corresponding
to the APOB mRNA species with constitutive exon 26 inclusion (top), pseudo 30 splice site activation (middle) and skipping of exon 26 (bottom)
are indicated on the right side. Fragment lengths in bp of the markers are indicated on the left side.
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effective when they are in single-stranded conformations,
which does not fit with our observation that the A6 region
(with the highest density of ESSs) is predicted to form
strong secondary structures, and more so than the A1 re-
gion which has a lower density of ESSs. Moreover, as the
formation of secondary structure by a particular sequence
is highly dependent on the context of its neighbouring
sequences, it is unclear how the ESSs, if they are working
primarily by means of mechanisms dependent on the for-
mation of secondary structure, could inhibit the splicing
of the two different heterologous splicing reporters used
here. For these reasons we believe that secondary struc-
ture may not be a key influence in pseudo splice site silen-
cing in exon 26.
Nonsense-mediated decay
In addition to regulation of splicing, other mechanisms
have been proposed to ensure that mature mRNAs
have been accurately spliced. Nonsense-mediated decay
(NMD) is conceivably a mechanism for suppressing
PTC-containing mRNAs generated by aberrant splicing
to cryptic splice sites, and is in some cases a mechanism
for regulation of protein expression [37]. However, des-
pite the fact that RNA editing generates a PTC in the
middle of exon 26, edited APOB mRNA appears to not
be subject to NMD, nor is a PTC-containing APOB
mRNA isoform skipping exon 27 [30]. In the case of
exon 26, the binding of the APOBEC-1 complementa-
tion factor (ACF), a component of the editosome, is im-
portant in protecting the edited RNA from NMD [38].
Further, out of the 37 alternative isoforms generated by
use of high-scoring pseudo splice sites in exon 26, 16
are predicted to splice in-frame and do not contain
PTCs. Therefore, NMD is not a plausible mechanism for
policing the selection of splice sites in APOB splicing.
Conclusions
The splicing of RNA requires the accurate selection of
genuine splice sites over numerous pseudo splice sites, and
this is facilitated by additional RNA sequence information
in the form of splicing enhancers and silencers. Accurate
splicing of exon 26 is necessary to ensure that APOB is
expressed correctly and assembled into the correct lipopro-
tein particles.
To our knowledge, this is the first time a partial survey
of splicing elements has been carried out in a long exon.
In most experimentally characterised cases, ESS have been
isolated as single elements or sometimes bipartite ele-
ments of variable length from 5 nt [39] to 119 nt [40],
usually in the context of alternative splicing. In exon 26,
our data demonstrate that there exist multiple, tandem
ESS, a unique configuration of ESS. We show, in vivo, that
blocking selected ESS with antisense oligonucleotides trig-
gers the selection of the strongest 30 pseudo splice site
within exon 26, i.e. cryptic activation of the pseudo splice
site. Although constitutive splicing of exon 26 at the na-
tive splice sites continues to generate the dominant iso-
form, and the alternative splicing effects are small, we
speculate that this may be ascribed to poor access of
blocking oligonucleotides to the spliceosome and the fact
that we have only targeted a small number of multiply re-
dundant ESS. This latter notion is supported by the fact
that blockade is only effective with combinations of ASOs.
We hypothesize that these multiple ESS may serve to
suppress the pseudo splice sites within it, and we
propose that similar mechanisms may govern the accur-
ate splicing of other long exons in the genome.
Furthermore, it is possible that polymorphisms within
the exon 26 sequence, even if translationally silent, may
perturb these silencers and disturb splicing of exon 26,
leading to subtle alterations of APOB expression and
function which may underlie inter-individual differences
in lipoprotein levels and function [41,42].
Methods
Computer analysis of sequences
The Homo sapiens genomic DNA sequence of APOB was
obtained from Ensembl (HUGO ID: APOB) [43]. The Spli-
ceSiteFinder server was used to scan exon 26 for potential
splice sites, scored according to the matrices of Shapiro
and Senapathy [4,44]. ESEfinder was used to scan for po-
tential SR protein binding sites [33,45]. The RESCUE-ESE
web server was used to scan for putative ESE hexamers
[9,46]. The FAS-ESS web server was used to scan for puta-
tive ESS hexamers [10,47]. The PESx web server was used
to scan for putative ESS as defined by Zhang and Chasin
[8,48]. Maximum Entropy Modelling [19] was additionally
used to scan exon 26 for potential splice sites.
Construction of DNA ligase III constructs
All oligonucleotides were obtained from Sigma-Genosys
Ltd., Cambridge, UK. 400 nt fragments of exon 26 were
amplified from human genomic DNA or HepG2 cDNA,
and coupled to T7 DNA ligase III C-ß DNA template [49]
by overlap-extension PCR [50] employing Phusion DNA
polymerase (Finnzymes OY, Finland). Sequences were con-
firmed by direct DNA sequencing. T7 DNA ligase III con-
structs containing 25-mer sequences from exon 26 were
constructed by PCR employing reverse oligonucleotides
containing the reverse-complement of the desired
sequence appended to the 50 end of the DNA ligase III
C-ß sequence. HßΔ6 constructs were made by annealing
complementary oligonucleotides containing the desired
25-nucleotide sequences with 50-CT and 50-AG overhangs,
and these were cloned into the AccI site within the second
exon of HßΔ6 [23,24]. Oligonucleotide sequences are avail-
able on request.
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In vitro analysis of splicing
Labelled, capped RNA transcripts were generated using the
appropriate RNA polymerase (Ambion, Inc., Huntingdon,
UK), 1 mM 7mG(ppp)G cap structure analogue (NEB,
Hitchin, UK), 0.5 mM each of ATP, UTP, CTP and
0.05 mM of GTP, and 5–10 μCi [α-32P] GTP (Perkin-Elmer
LAS Ltd., Beaconsfield, UK) [51]. 20 fmol of labelled RNA
was employed in in vitro splicing reactions with 10 μl
of HeLa nuclear extract (Computer Cell Culture, Mons,
Belgium) for 1 hour at 30°C (DNA ligase III constructs),
2 hours at 30°C (HßΔ6 constructs) or on ice as indicated
[52]. Purified spliced RNA was analysed with 5% or 10%
urea-PAGE (Sequagel, National Diagnostics, Hessle, UK)
and autoradiography. Quantification of autoradiographs
was performed using FujiFilm Image Gauge software ver-
sion 4.2 (FujiFilm Medical Systems, Stamford, CT, USA).
Antisense oligonucleotide transfection of HepG2 cells
HepG2 cells were maintained in Minimum Essential Medium
with Earle’s salts and glutamine, 10% fetal bovine serum
(Gibco/Invitrogen, Paisley, UK) at 37°C under 5% CO2. 2
0-O-
methyl ASOs were ordered from Dharmacon (Lafayette,
CO, USA). The sequences (50-30) of the ASOs were as
follows: ASO 65–89 GAUAUUCGAAUCUAGAAAUUUG
UGG; ASO 97–121 UUGUUUCCAAGUUUUUCUACAU
GAC; ASO 129–153 CAUCGAAUAUUAGUAAACCUUU
UGA; ASO 2319–2343 CUUUAAAUAUACUGAUCAAAU
UGUA; ASO 93–217 UGCUGUUUCUUUUUGGAGUCCA
AAU; negative control ASO GGCCGAUCCGUCAGUCCA.
ASOs were transfected in 12-well plates, with 1 × 106
cells per well, using 2.4 μl Lipofectamine 2000 in 200 μl
OptiMEM I (Invitrogen) as per the manufacturer’s
protocol, then incubated for 48 hours before harvesting.
Total RNA was isolated from cells using the RNeasy
Micro kit (Qiagen, Crawley, UK). The RNA concentra-
tion was quantified using the NanoDrop 1000 (Thermo
Scientific, Waltham, MA, USA), and 2.5 μg was reverse-
transcribed using Transcriptor reverse transcriptase
(Roche Applied Science, Burgess Hill, UK) with an oligo
dT15 primer as per the manufacturer’s protocol. 0.25 μl of
the cDNA was then analysed in an RT-PCR reaction with
Exl DNA polymerase (Stratagene, La Jolla, CA, USA) and
0.5 μCi [α-32P]-dCTP (Amersham, Little Chalfont, UK)
using the following primers: forward (exon 25) GCCA
TCTCGAGAGTTCCAAG and reverse (exon 27) GTCA
CGGTGTGCAAATGTTC according to the manufac-
turer’s instructions. The PCR reaction was then subjected
to PAGE on a non-denaturing 6% gel, and autoradio-
graphed. The identity of each PCR product of interest was
confirmed by excision and sequencing.
Statistical analysis
Statistical analysis was performed using Prism version
4.0c (GraphPad Software, Inc., San Diego, CA, USA).
Comparisons between quantitated datasets were
performed using one-way ANOVA. Bonferroni’s test
was used to analyse the differences in splicing effi-
ciency between individual constructs and control
constructs.
Additional files
Additional file 1: Table S1. Shapiro and Senapathy [4] scores for the
splice sites flanking the internal exons 2–28 of APOB.
Additional file 2: Table S2. Maximum Entropy Modelling scores [19]
for 30 and 5’ splice sites. Only motifs with higher scores than the native
splice sites (italics) shown. Branch point sequences motifs with
appropriate strength (score >70) and positioned within 50 nucleotides of
a 30 splice site capable of generating a pseudoexon [20].
Additional file 3: Figure S1. Antisense oligonucleotides directed
against identified ESS elements of APOB exon 26 in HepG2 cells –
additional control oligonucleotide included. In lanes 1 and 2 the cells
were not transfected with ASOs. The –RT control PCR (lane 1) was
performed without reverse transcriptase. Lanes 3–6 were transfected with
the indicated ASOs at 250 nM each. An additional control
oligonucleotide targeting a neutral sequence is shown in lane 6. Cells
were incubated for 48 hours and RT-PCR was carried out on the total
RNA extracted from these cells with oligonucleotides annealing to the
adjacent exons 25 and 27. The positions of the bands corresponding to
the APOB mRNA species with constitutive exon 26 inclusion (top), pseudo
30 splice site activation (middle) and skipping of exon 26 (bottom) are
indicated on the right side. Fragment lengths in bp of the markers are
indicated on the left side.
Additional file 4: Figure S2. Frequency of FAS-ESS hex2 hexamers in
the APOB exon 26 sequence. FAS-ESS hex2 subset refers to those
hexamers found at least twice within recovered decamers from the FAS-
ESS procedure [47]. Hexamers were counted in a non-overlapping 16 bp
windows and normalised to the number of possible hexamers per 16 nt.
Blue line shows normalised hexamer ratio plotted for each window. Black
line shows a moving average over 5 windows.
Additional file 5: Figure S3. Computational identification of potential
ESS sequences within the exon 26 sequence. The exon 26 sequence is
shown in black, with numbers above denoting the position in exon 26.
25-mers tested in the DNA ligase III reporter system are shown below the
exon 26 sequence, sequences with ESS activity are denoted by white-on-
black text, neutral sequences are denoted by black-on-white text.
Sequences containing hexamers identified by the FAS-ESS server
program are in bold [47]. Matches to the PESS sequences identified by
Zhang and Chasin [8] are underlined.
Additional file 6: Figure S4. Computational identification of potential
ESS sequences within the exon 26 sequence derived from fragment 6.
The exon 26 sequence is shown in black, with numbers above denoting
the position in exon 26. 25-mers tested in the DNA ligase III reporter
system are shown below the exon 26 sequence, sequences with ESS
activity are denoted by white-on-black text, neutral sequences are
denoted by black-on-white text. Sequences containing hexamers
identified by the FAS-ESS server program are in bold [47]. Matches to the
PESS sequences identified by Zhang and Chasin [8] are underlined.
Additional file 7: Table S3. Degree of base-pairing secondary structure
predicted for regions of APOB exon 26 using the Mfold web server [35].
These include the native 30 and 50 splice sites, parts of region A1 (1–281)
and A6 (2143–2407) investigated in vitro (see Figures 2 & 3) and the
regions of exon 26 targeted by the ASOs 1–6. Secondary structure was
analysed using the whole of exon 26 in addition to the entire length of
the adjacent introns either side. Figures shown are the number of
nucleotides predicted to be base-paired using the 4 most stable
structures predicted (range of ΔG −2245.70 to −2244.2 kcal/mol) Final
column gives the average number of nucleotides base-paired and the %
nucleotides base-paired for the given sequences.
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